At KLOWs fixed ratio, delivering 2 mg of TB-4 would require 16 mg total KLOW: 10 mg GHK-Cu and 2 mg each of BPC-157, TB-4, and KPV an absurdly high, potentially dangerous amount of GHK-Cu
These studies have contributed to understanding the potential role of NNMT in metabolic disorders
NAD+ is the primary metabolic add-on for KLOW because collagen and tissue remodeling are energy-intensive: repair cells need NAD+ to produce energy, repair DNA, and keep building new tissue
Side Effects & Safety Mild GI discomfort most common, usually transient in the first week Slight stimulant effect increased energy/alertness, especially early on Headaches occasional, typically mild and dose-related Mild insomnia if taken too late in the day No human clinical safety data all safety information from preclinical studies and community reports No liver toxicity observed in animal studies at therapeutic doses Unknown drug interactions theoretically could interact with NAD+-dependent pathways Core Supplies for This Protocol The three essentials for running any reconstituted injectable: cold storage, accurate syringes, and metabolic tracking
Domestic USA Manufacturing: Formulated and packaged in state-of-the-art US facilities adhering to stringent quality standards
